ISDA: 8GBU

Deposition Date 2023-02-28

Release Date 2023-09-06

Last Version Date 2024-10-09

Entry Detail

PDB ID:

8GBU

Keywords:

VIRAL PROTEIN

Title:

Hepatitis B capsid Y132A mutant with compound AB-506

Biological Source:

Source Organism(s):

Hepatitis B virus (Taxon ID: 10407)

Expression System(s):

Escherichia coli

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

2.50 Å

R-Value Free:

0.28

R-Value Work:

0.23

R-Value Observed:

0.23

Space Group:

C 1 2 1

Download Validation Report

Macromolecular Entities

Structures with similar UniProt ID

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Capsid protein
Chain IDs:A, B, C, D, E, F
Chain Length:167
Number of Molecules:6
Biological Source:Hepatitis B virus

UniProt ID:P03147 Pfam ID:PF00906

Ligand Molecules

EDO

YWE

Primary Citation

Design, synthesis, and structure-activity relationship of a bicyclic HBV capsid assembly modulator chemotype leading to the identification of clinical candidate AB-506.

Cole, A.G, Kultgen, S.G, Mani, N, Quintero, J.G, Yi Fan, K, Ardzinski, A, Stever, K, Dorsey, B.D, Phelps, J.R, Lee, A.C.H, Thi, E.P, Chiu, T, Tang, S, Horanyi, P.S, Mayclin, S.J, Harasym, T.O, Sofia, M.J.Show

Bioorg.Med.Chem.Lett. 94 129456 129456 (2023)

PMID: 37633618 DOI: 10.1016/j.bmcl.2023.129456

Abstact

Disruption of the HBV capsid assembly process through small-molecule interaction with HBV core protein is a validated target for the suppression of hepatitis B viral replication and the development of new antivirals. Through combination of key structural features associated with two distinct series of capsid assembly modulators, a novel aminochroman-based chemotype was identified. Optimization of anti-HBV potency through generation of SAR in addition to further core modifications provided a series of related functionalized aminoindanes. Key compounds demonstrated excellent cellular potency in addition to favorable ADME and pharmacokinetic profiles and were shown to be highly efficacious in a mouse model of HBV replication. Aminoindane derivative AB-506 was subsequently advanced into clinical development.

Legend

Protein

Chemical

Disease

Primary Citation of related structures

Abstact

Feedback Form